PRCT

Procept Biorobotics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 5/10
  • Value↓ 1/10
Procept Biorobotics sales and earnings growth
PRCT Growth
Neutral
  • Revenue Y/Y↑ 25.66%
  • EPS Y/Y↓ -7.69%
  • FCF Y/Y↑ 8.66%
Procept Biorobotics gross and profit margin trends
PRCT Profitability
Neutral
  • Gross margin ↑ 64.00%
  • EPS margin↓ -31.80%
  • ROIC 5Y↓ -53.01%
Procept Biorobotics net debt vs free cash flow
PRCT Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -13.0

Procept Biorobotics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Medical Devices stocks